Novel Domain of LRP Cytoplasmic Tail in APP Processing
Principal Investigator
Project Goals
We hypothesize that the LRP-C37 domain plays a critical role in transporting LRP and APP to compartments where Ab is normally generated. In this application, we propose to characterize the mechanistic basis of the LRP-C37 domain in LRP and APP transport inside cells and Ab generation. In addition, we will determine the role of the two new LRP-C37 interacting proteins in these processes.
Project Summary
Alzheimer's disease (AD) is a progressive and irreversible disease of the brain leading to deterioration of mental function and eventual morbidity and death. The major defining characteristic of AD brains is the excessive accumulation of amyloid plaques, composed of a sticky protein called amyloid b (Ab). Ab is toxic to nerve cells, and this may explain the progressive degeneration seen in AD brains. Ab is formed when 'molecular scissors' cut APP into 2 places, resulting in the release of Ab. This is a normal process that also occurs in healthy individuals. However, for reasons we do not understand at present, Ab is either excessively produced or not removed fast enough in AD patients. One obvious way to block Ab formation is to inactivate the 'molecular scissors'. However, these proteins also have other important functions, such that blocking the 'molecular scissors' can have undesirable side effects. An alternative and perhaps additive design might be to block APP transport inside nerve cells so that it does not reach the sites where the 'molecular scissors' reside and are most active. In our studies, we found that a protein called LRP normally promotes Ab generation by directing the transport of APP inside cells to compartments where the 'molecular scissors' are most active. More than 80% of Ab production is dependent on the presence of LRP. Remarkably, we found that a very small region of LRP (LRP-C37) by itself is sufficient to mimic LRP in robustly increasing Ab generation. In addition, we identified new proteins that physically interact with the C37 domain and modify the cuts made in APP. At present, how LRP-C37 by itself or in the context of the full protein increases Ab production is not known. Furthermore, it is not known how the two new proteins we identified alter APP processing and Ab generation. We hypothesize that the LRP-C37 domain plays a critical role in transporting LRP and APP to compartments where Ab is normally generated. In this application, we propose to characterize the mechanistic basis of the LRP-C37 domain in LRP and APP transport inside cells and Ab generation. In addition, we will determine the role of the two new LRP-C37 interacting proteins in these processes. These studies are expected to form the basis of designing a novel therapeutic approach to block Ab generation.
Progress Updates
Dr. David Kang and collaborators recently found that a protein called LRP normally promotes generation of toxic beta-amyloid protein by moving its precursor protein, called APP, inside cells into compartments where the “molecular scissors” are most active. More than 80% of beta-amyloid production is dependent on the presence of LRP protein. However, the specific cause of this increased LRP-mediated transport and APP processing is unknown.
With the support of this BrightFocus award, Dr. Kang and collaborators discovered that a very small region of LRP (called LRP-C37) by itself is sufficient to mimic LRP's ability to increase generation of beta-amyloid. More specifically, they found that certain parts of the LRP-C37 region dictate how much beta-amyloid is produced. In addition, they identified a new scaffolding protein, called RanBP9, which physically interacts with LRP-C37 to modify the cuts made in APP. This is an important finding, because RanBP9 is increased in the brains of individuals with Alzheimer's disease. Therefore, RanBP9 is responsible for directing APP transport to domains inside cells where the “molecular scissors” are most active. Blocking the LRP-RanBP9 interaction might be a new and attractive way of therapeutically stemming beta-amyloid production, and the resulting nerve cell damage, in Alzheimer's disease.
Publications
Lakshmana, M.K., Yoon, I., Chen, E., and Kang, D.E.* (2008). C-terminal 37 residues of LRP promote the amyloidogenic processing of APP independent of FE65. J. Cell. Mol. Med. 12, 2665-2674. 
Lakshmana MK, Yoon IS, Chen E, Bianchi E, Koo EH, Kang DE. (2009). Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation. J. Biol. Chem. 284(18):11863-72.
Lakshmana MK, Chung JY, Wickramarachchi S, Tak E, Bianchi E, Koo EH, Kang DE. (2010). A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid-beta peptide generation. FASEB J. 24(1):119-27.
Boo JH, Song H, Kim JE, Kang DE, Mook-Jung I. (2009). Accumulation of phosphorylated beta-catenin enhances ROS-induced cell death in presenilin-deficient cells. PLoS One. 2009;4(1):e4172. Epub 2009 Jan 12.
Cheung KH, Mei L, Mak DO, Hayashi I, Iwatsubo T, Kang DE, Foskett JK. (2010). Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. Sci Signal. 2010 Mar 23;3(114):ra22.
First published on: June 11, 2008
Last modified on: November 20, 2024